Search Site
Home >> Signaling Pathways >> Apoptosis >> MDM2 >> JNJ-26854165 (Serdemetan)
Related Products
JNJ-26854165 (Serdemetan)
P53 activator, blocking Mdm2-p53 interaction

JNJ-26854165 (Serdemetan)

Catalog No. A4204
Size Price Stock Qty
10mM (in 1mL DMSO) $100.00 In stock
Evaluation Sample $28.00 In stock
5mg $80.00 In stock
25mg $260.00 In stock
100mg $680.00 In stock

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

JNJ-26854165 (Serdemetan)

Related Biological Data

JNJ-26854165 (Serdemetan)

Related Biological Data

JNJ-26854165 (Serdemetan)

Biological Activity

Description JNJ-26854165 (Serdemetan) is an antagonist of HDM2 ubiquitin ligase and also inducer of early apoptosis in p53 wild-type cells,
Targets HDM2 Mdm2        
IC50            

Protocol

Cell experiment [1]:

Cell lines

H460, A549 cells, and HMEC-1 endothelial cells

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

0.5, 1, 2.5, 5, 10, 25 and 50 μM; 48 h

Applications

After 48 h treatment, Serdemetan inhibited cell proliferation with IC50 values of 3.9 μM, and 8.7 μM for H460 cells and A549 cells, respectively. Moreover, Serdemetan at 5 μM inhibited HMEC-1 endothelial cell migration.

Animal experiment [1]:

Animal models

H460 and A549 cells, injected in the right flank of nude mice were grown as tumor xenografts.

Dosage form

50 mg/kg; p.o. twice a week, for 2 weeks

Applications

Serdemetan treatment significantly enhanced radiation-induced growth delays in A549 and H460 xenograft tumors.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

1Chargari, C., Leteur, C., Angevin, E., Bashir, T., Schoentjes, B., Arts, J., Janicot, M., Bourhis, J. and Deutsch, E. (2011) Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett. 312, 209-218

JNJ-26854165 (Serdemetan) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

JNJ-26854165 (Serdemetan) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 881202-45-5 SDF Download SDF
Synonyms JNJ 26854165
Chemical Name 1-N-[2-(1H-indol-3-yl)ethyl]-4-N-pyridin-4-ylbenzene-1,4-diamine
Canonical SMILES C1=CC=C2C(=C1)C(=CN2)CCNC3=CC=C(C=C3)NC4=CC=NC=C4
Formula C21H20N4 M.Wt 328.41
Solubility Soluble in DMSO > 10 mM Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

Background

JNJ-26854165, also named as Serdemetan, is originally developed as an activator of p53, is now regarded as a novel oral Human Double Minute-2 (HDM-2) ubiquitin ligase antagonist. It can increase the level of HDM-2 client proteins, such as p53, by inhibiting the association of HDM-2-client protein complex with the proteosome. It is demonstrated potent anti-proliferative and apoptosis-inducing activity of JNJ-26854165 in a broad range of p53 wild type and mutant tumor models. In vivo, JNJ-26854165 may induce important differences in EFS distribution when comparing to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts.

Reference

J. Tabernero, L. Dirix, P. Schoffski, A. Cervantes, J. Capdevila, J. Baselga, L. van Beijsterveldt, H. Winkler, S. Kraljevic and S. H. Zhuang. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors. Journal of Clinical Oncology (Meeting Abstracts) May 2009 vol. 27 no. 15S 3514

Malcolm A. Smith, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, John M. Maris, Stephen T. Keir, Christopher L. Morton, C. Patrick Reynolds, Min H. Kang, Janine Arts, Tarig Bashir, Michel Janicot, Raushan T. Kurmasheva, Peter J. Houghton. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatric Blood & Cancer. Volume 59, Issue 2, pages 329–332, August 2012.